Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company Drug

NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma

Fineline Cube Aug 11, 2023

The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...

Company Medical Device

Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China

Fineline Cube Aug 11, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...

Company Deals

WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership

Fineline Cube Aug 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Deals

Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China

Fineline Cube Aug 11, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

Fineline Cube Aug 11, 2023

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...

Company Legal / IP

Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China

Fineline Cube Aug 11, 2023

A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...

Company

Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars

Fineline Cube Aug 10, 2023

US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002

Fineline Cube Aug 10, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Medical Device

Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China

Fineline Cube Aug 10, 2023

Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...

Company Deals

Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development

Fineline Cube Aug 10, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...

Company Drug

Novartis Reports Positive Phase III Results for Remibrutinib in Chronic Spontaneous Urticaria

Fineline Cube Aug 10, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has announced positive data from the Phase III...

Company Deals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

Fineline Cube Aug 9, 2023

Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...

Company Policy / Regulatory

Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry

Fineline Cube Aug 9, 2023

An audit has shed light on the use of third-party business promotion companies as a...

Company

Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 9, 2023

US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...

Company

FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising

Fineline Cube Aug 9, 2023

US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...

Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Fineline Cube Aug 9, 2023

Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...

Company Drug

Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial

Fineline Cube Aug 9, 2023

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...

Posts pagination

1 … 529 530 531 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.